{"url_path":"/sec/bbio/8-k/2026-07-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","accession_number":"0001140361-26-027445","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":124,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\n \n\nOn July 1, 2026, the Company issued a press release announcing the transactions described in Item 1.01 of this Current Report on Form\n8-K. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange\nAct, except as shall be expressly set forth by specific reference in such filing."}